Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal investigation of thromboembolism etiology (LITE)

Albert W. Tsai, Mary Cushman, Michael Y. Tsai, Susan R. Heckbert, Wayne D. Rosamond, Nena Aleksic, N. David Yanez, Bruce M. Psaty, Aaron R. Folsom

Research output: Contribution to journalArticle

59 Scopus citations


We sought to examine prospectively the association of serum homocysteine and the methylene tetrahydrofolate reductase (MTHFR) C677T gene polymorphism with risk of venous thromboembolism (VTE). We studied these relationships in a nested case-control study of 303 VTE cases and 635 matched controls from a population-based cohort of 21,680 adults from six U.S. communities. The highest quintile of serum homocysteine carried a non-statistically significant adjusted odds ratio of 1.55 (95% CI, 0.93-2.58) compared to the lowest quintile in the overall cohort but a significant association among adults aged 45-64 years (OR = 2.05, 95% CI, 1.10-3.83) and an inverse association in those ≥65 years of age. Carriers of the MTHFR C677T polymorphism were not at higher risk for VTE than those with normal genotype (OR = 0.74, 95% CI = 0.56-0.98). Our prospective data showed, at most, a weak relationship between homocysteine and VTE risk, with associations larger among younger participants. MTHFR C677T was not a risk factor for VTE.

Original languageEnglish (US)
Pages (from-to)192-200
Number of pages9
JournalAmerican Journal of Hematology
Issue number3
StatePublished - Mar 1 2003



  • Deep vein thrombosis
  • Epidemiology
  • Homocysteine
  • Pulmonary embolism

ASJC Scopus subject areas

  • Hematology

Cite this